AT503317B1 - Verwendung von gallium(iii)-komplexen zur herstellung eines medikaments zur behandlung von melanomen - Google Patents
Verwendung von gallium(iii)-komplexen zur herstellung eines medikaments zur behandlung von melanomen Download PDFInfo
- Publication number
- AT503317B1 AT503317B1 AT0022006A AT2202006A AT503317B1 AT 503317 B1 AT503317 B1 AT 503317B1 AT 0022006 A AT0022006 A AT 0022006A AT 2202006 A AT2202006 A AT 2202006A AT 503317 B1 AT503317 B1 AT 503317B1
- Authority
- AT
- Austria
- Prior art keywords
- compound according
- cycloalkyl
- alkyl
- aryl
- heteroaryl
- Prior art date
Links
- 239000003814 drug Substances 0.000 title claims description 20
- 201000001441 melanoma Diseases 0.000 title claims description 14
- 238000004519 manufacturing process Methods 0.000 title claims description 7
- CKHJYUSOUQDYEN-UHFFFAOYSA-N gallium(3+) Chemical class [Ga+3] CKHJYUSOUQDYEN-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims description 31
- 125000003118 aryl group Chemical group 0.000 claims description 25
- GYHNNYVSQQEPJS-UHFFFAOYSA-N Gallium Chemical compound [Ga] GYHNNYVSQQEPJS-UHFFFAOYSA-N 0.000 claims description 22
- 229910052733 gallium Inorganic materials 0.000 claims description 19
- 125000000217 alkyl group Chemical group 0.000 claims description 14
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 14
- 125000001072 heteroaryl group Chemical group 0.000 claims description 14
- 206010028980 Neoplasm Diseases 0.000 claims description 12
- 229940079593 drug Drugs 0.000 claims description 11
- 125000000623 heterocyclic group Chemical group 0.000 claims description 10
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 claims description 8
- -1 phosphatides Substances 0.000 claims description 7
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 6
- 235000003599 food sweetener Nutrition 0.000 claims description 6
- 239000003765 sweetening agent Substances 0.000 claims description 6
- 229910052736 halogen Inorganic materials 0.000 claims description 5
- 150000002367 halogens Chemical class 0.000 claims description 5
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 5
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 4
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 4
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 3
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 claims description 3
- 229920000084 Gum arabic Polymers 0.000 claims description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 3
- 240000007817 Olea europaea Species 0.000 claims description 3
- 239000005662 Paraffin oil Substances 0.000 claims description 3
- 235000010489 acacia gum Nutrition 0.000 claims description 3
- 125000004122 cyclic group Chemical group 0.000 claims description 3
- 239000000839 emulsion Substances 0.000 claims description 3
- 239000000796 flavoring agent Substances 0.000 claims description 3
- 235000013355 food flavoring agent Nutrition 0.000 claims description 3
- 239000001257 hydrogen Substances 0.000 claims description 3
- 229910052739 hydrogen Inorganic materials 0.000 claims description 3
- 239000008101 lactose Substances 0.000 claims description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 3
- 239000004006 olive oil Substances 0.000 claims description 3
- 239000003755 preservative agent Substances 0.000 claims description 3
- 239000000243 solution Substances 0.000 claims description 3
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 2
- 235000017060 Arachis glabrata Nutrition 0.000 claims description 2
- 244000105624 Arachis hypogaea Species 0.000 claims description 2
- 235000010777 Arachis hypogaea Nutrition 0.000 claims description 2
- 235000018262 Arachis monticola Nutrition 0.000 claims description 2
- 125000004406 C3-C8 cycloalkylene group Chemical group 0.000 claims description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
- 206010027476 Metastases Diseases 0.000 claims description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 2
- 229930006000 Sucrose Natural products 0.000 claims description 2
- 229920001615 Tragacanth Polymers 0.000 claims description 2
- 150000001450 anions Chemical class 0.000 claims description 2
- 239000000305 astragalus gummifer gum Substances 0.000 claims description 2
- 239000000460 chlorine Substances 0.000 claims description 2
- 229910052801 chlorine Inorganic materials 0.000 claims description 2
- 239000003086 colorant Substances 0.000 claims description 2
- 230000001472 cytotoxic effect Effects 0.000 claims description 2
- 239000008121 dextrose Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 claims description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
- 229960004903 invert sugar Drugs 0.000 claims description 2
- 125000002950 monocyclic group Chemical group 0.000 claims description 2
- 238000007911 parenteral administration Methods 0.000 claims description 2
- 235000020232 peanut Nutrition 0.000 claims description 2
- 239000000312 peanut oil Substances 0.000 claims description 2
- LZFIOSVZIQOVFW-UHFFFAOYSA-N propyl 2-hydroxybenzoate Chemical class CCCOC(=O)C1=CC=CC=C1O LZFIOSVZIQOVFW-UHFFFAOYSA-N 0.000 claims description 2
- 125000002577 pseudohalo group Chemical group 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 235000020374 simple syrup Nutrition 0.000 claims description 2
- 239000005720 sucrose Substances 0.000 claims description 2
- 239000002562 thickening agent Substances 0.000 claims description 2
- 239000007864 aqueous solution Substances 0.000 claims 2
- 125000005843 halogen group Chemical group 0.000 claims 2
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 claims 1
- 235000006491 Acacia senegal Nutrition 0.000 claims 1
- 244000165918 Eucalyptus papuana Species 0.000 claims 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 1
- 238000004113 cell culture Methods 0.000 claims 1
- 239000003995 emulsifying agent Substances 0.000 claims 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims 1
- 229920000053 polysorbate 80 Polymers 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 235000011069 sorbitan monooleate Nutrition 0.000 claims 1
- 239000001593 sorbitan monooleate Substances 0.000 claims 1
- 229940035049 sorbitan monooleate Drugs 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 description 8
- CHPZKNULDCNCBW-UHFFFAOYSA-N gallium nitrate Chemical compound [Ga+3].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O CHPZKNULDCNCBW-UHFFFAOYSA-N 0.000 description 6
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- 150000002258 gallium Chemical class 0.000 description 4
- 229940044658 gallium nitrate Drugs 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 2
- 239000000205 acacia gum Substances 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 125000000392 cycloalkenyl group Chemical group 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 125000006833 (C1-C5) alkylene group Chemical group 0.000 description 1
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 description 1
- VXNZUUAINFGPBY-UHFFFAOYSA-N 1-Butene Chemical group CCC=C VXNZUUAINFGPBY-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- ASYYOZSDALANRF-UHFFFAOYSA-K 3-bis[(2-methyl-4-oxopyran-3-yl)oxy]gallanyloxy-2-methylpyran-4-one Chemical group [Ga+3].CC=1OC=CC(=O)C=1[O-].CC=1OC=CC(=O)C=1[O-].CC=1OC=CC(=O)C=1[O-] ASYYOZSDALANRF-UHFFFAOYSA-K 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 240000002470 Amphicarpaea bracteata Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 244000060011 Cocos nucifera Species 0.000 description 1
- 235000013162 Cocos nucifera Nutrition 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- UDIPTWFVPPPURJ-UHFFFAOYSA-M Cyclamate Chemical compound [Na+].[O-]S(=O)(=O)NC1CCCCC1 UDIPTWFVPPPURJ-UHFFFAOYSA-M 0.000 description 1
- 208000029966 Hutchinson Melanotic Freckle Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 208000037147 Hypercalcaemia Diseases 0.000 description 1
- 206010024218 Lentigo maligna Diseases 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 206010027145 Melanocytic naevus Diseases 0.000 description 1
- 206010029155 Nephropathy toxic Diseases 0.000 description 1
- 208000007256 Nevus Diseases 0.000 description 1
- 206010029488 Nodular melanoma Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 102000000505 Ribonucleotide Reductases Human genes 0.000 description 1
- 108010041388 Ribonucleotide Reductases Proteins 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 244000000231 Sesamum indicum Species 0.000 description 1
- 235000003434 Sesamum indicum Nutrition 0.000 description 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 description 1
- 240000006394 Sorghum bicolor Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- WERKSKAQRVDLDW-ANOHMWSOSA-N [(2s,3r,4r,5r)-2,3,4,5,6-pentahydroxyhexyl] (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO WERKSKAQRVDLDW-ANOHMWSOSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- IYABWNGZIDDRAK-UHFFFAOYSA-N allene Chemical group C=C=C IYABWNGZIDDRAK-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 229940063655 aluminum stearate Drugs 0.000 description 1
- 208000006431 amelanotic melanoma Diseases 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 125000000732 arylene group Chemical group 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000005569 butenylene group Chemical group 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000000625 cyclamic acid and its Na and Ca salt Substances 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000004976 cyclobutylene group Chemical group 0.000 description 1
- 125000005725 cyclohexenylene group Chemical group 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000004956 cyclohexylene group Chemical group 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000004979 cyclopentylene group Chemical group 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 125000004980 cyclopropylene group Chemical group 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 125000005678 ethenylene group Chemical group [H]C([*:1])=C([H])[*:2] 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 150000002259 gallium compounds Chemical class 0.000 description 1
- UPWPDUACHOATKO-UHFFFAOYSA-K gallium trichloride Chemical compound Cl[Ga](Cl)Cl UPWPDUACHOATKO-UHFFFAOYSA-K 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 230000000148 hypercalcaemia Effects 0.000 description 1
- 208000030915 hypercalcemia disease Diseases 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 150000002484 inorganic compounds Chemical class 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 201000010078 malignant spindle cell melanoma Diseases 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000007694 nephrotoxicity Effects 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 201000000032 nodular malignant melanoma Diseases 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- HRGDZIGMBDGFTC-UHFFFAOYSA-N platinum(2+) Chemical class [Pt+2] HRGDZIGMBDGFTC-UHFFFAOYSA-N 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 125000006410 propenylene group Chemical group 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 229910001467 sodium calcium phosphate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 229960001462 sodium cyclamate Drugs 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 208000019798 spindle cell melanoma Diseases 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 238000009492 tablet coating Methods 0.000 description 1
- 239000002700 tablet coating Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- GBXQPDCOMJJCMJ-UHFFFAOYSA-M trimethyl-[6-(trimethylazaniumyl)hexyl]azanium;bromide Chemical compound [Br-].C[N+](C)(C)CCCCCC[N+](C)(C)C GBXQPDCOMJJCMJ-UHFFFAOYSA-M 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 208000016261 weight loss Diseases 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Quinoline Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Priority Applications (13)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AT0022006A AT503317B1 (de) | 2006-02-13 | 2006-02-13 | Verwendung von gallium(iii)-komplexen zur herstellung eines medikaments zur behandlung von melanomen |
| CA2640509A CA2640509C (en) | 2006-02-13 | 2007-02-13 | Use of gallium(iii) complexes for the treatment of melanomas |
| DE502007006880T DE502007006880D1 (de) | 2006-02-13 | 2007-02-13 | Verwendung von gallium (iii) komplexen zur behandlung von melanomen |
| PT07701315T PT1984005E (pt) | 2006-02-13 | 2007-02-13 | Uso de complexos de gálio para o tratamento de melanomas |
| AT07701315T ATE504307T1 (de) | 2006-02-13 | 2007-02-13 | Verwendung von gallium (iii) komplexen zur behandlung von melanomen |
| AU2007215363A AU2007215363A1 (en) | 2006-02-13 | 2007-02-13 | Use of gallium(III) complexes for the treatment of melanomas |
| JP2008553574A JP5210888B2 (ja) | 2006-02-13 | 2007-02-13 | 黒色腫の治療のためのガリウム（ｉｉｉ）錯体の使用 |
| NZ571119A NZ571119A (en) | 2006-02-13 | 2007-02-13 | Use of tris(hydroxyquinolinolato)gallium(III) for the treatment of melanomas |
| ES07701315T ES2365028T3 (es) | 2006-02-13 | 2007-02-13 | Uso de complejos de galio(iii) para el tratamiento de melanomas. |
| PCT/AT2007/000071 WO2007092978A1 (de) | 2006-02-13 | 2007-02-13 | Verwendung von gallium (iii) komplexen zur behandlung von melanomen |
| EP07701315A EP1984005B1 (de) | 2006-02-13 | 2007-02-13 | Verwendung von gallium (iii) komplexen zur behandlung von melanomen |
| CNA2007800127458A CN101466387A (zh) | 2006-02-13 | 2007-02-13 | 镓(ⅲ)络合物在黑素瘤治疗中的应用 |
| US12/190,759 US7919486B2 (en) | 2006-02-13 | 2008-08-13 | Use of gallium(III) complexes for the treatment of melanomas |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AT0022006A AT503317B1 (de) | 2006-02-13 | 2006-02-13 | Verwendung von gallium(iii)-komplexen zur herstellung eines medikaments zur behandlung von melanomen |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AT503317B1 true AT503317B1 (de) | 2007-09-15 |
| AT503317A4 AT503317A4 (de) | 2007-09-15 |
Family
ID=37969931
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT0022006A AT503317B1 (de) | 2006-02-13 | 2006-02-13 | Verwendung von gallium(iii)-komplexen zur herstellung eines medikaments zur behandlung von melanomen |
| AT07701315T ATE504307T1 (de) | 2006-02-13 | 2007-02-13 | Verwendung von gallium (iii) komplexen zur behandlung von melanomen |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT07701315T ATE504307T1 (de) | 2006-02-13 | 2007-02-13 | Verwendung von gallium (iii) komplexen zur behandlung von melanomen |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US7919486B2 (enExample) |
| EP (1) | EP1984005B1 (enExample) |
| JP (1) | JP5210888B2 (enExample) |
| CN (1) | CN101466387A (enExample) |
| AT (2) | AT503317B1 (enExample) |
| AU (1) | AU2007215363A1 (enExample) |
| CA (1) | CA2640509C (enExample) |
| DE (1) | DE502007006880D1 (enExample) |
| ES (1) | ES2365028T3 (enExample) |
| NZ (1) | NZ571119A (enExample) |
| PT (1) | PT1984005E (enExample) |
| WO (1) | WO2007092978A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101783676B1 (ko) | 2010-02-12 | 2017-10-10 | 니키 파머 액퀴지션 코포레이션 2 | 혈액암의 치료 방법 |
| ES2527358T3 (es) * | 2010-02-26 | 2015-01-22 | Niiki Pharma Inc. | Compuesto para el tratamiento de cáncer cerebral |
| CN102946879B (zh) * | 2010-04-19 | 2015-04-22 | 尼基制药公司 | 一种蛋白酶体抑制剂和镓络合物在制备治疗增殖性疾病的药物中的应用 |
| JP6112512B2 (ja) * | 2010-12-01 | 2017-04-12 | レクシ ファーマ インコーポレイテッド | 難治性癌を治療するための方法 |
| CN113372269A (zh) * | 2021-06-25 | 2021-09-10 | 云南大学 | 一种席夫碱镓配合物及其制备方法和应用 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5525598A (en) * | 1991-07-25 | 1996-06-11 | Phillippe Collery | Gallium (III) complexes in pharmaceutical compositions |
| WO2002074304A2 (de) * | 2001-03-19 | 2002-09-26 | Faustus Forschungs Cie. Translational Cancer Research Gmbh | Zusammensetzung, enthaltend einen gallium(iii)-komplex und ein therapeutisch wirksames zytostatikum |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10116527C2 (de) * | 2001-04-03 | 2003-05-15 | Faustus Forschungs Cie | Tumorhemmende Galliumverbindungen, deren Verwendung als Arzneimittel sowie ein Arzneimittel, diese enthaltend |
| AT501819B1 (de) * | 2005-04-18 | 2007-01-15 | Faustus Forschung Translationa | Verwendung von gallium(iii)-komplexen zur behandlung von tumorerkrankungen der leber |
-
2006
- 2006-02-13 AT AT0022006A patent/AT503317B1/de not_active IP Right Cessation
-
2007
- 2007-02-13 AU AU2007215363A patent/AU2007215363A1/en not_active Abandoned
- 2007-02-13 CN CNA2007800127458A patent/CN101466387A/zh active Pending
- 2007-02-13 JP JP2008553574A patent/JP5210888B2/ja not_active Expired - Fee Related
- 2007-02-13 CA CA2640509A patent/CA2640509C/en not_active Expired - Fee Related
- 2007-02-13 AT AT07701315T patent/ATE504307T1/de active
- 2007-02-13 DE DE502007006880T patent/DE502007006880D1/de active Active
- 2007-02-13 PT PT07701315T patent/PT1984005E/pt unknown
- 2007-02-13 NZ NZ571119A patent/NZ571119A/en not_active IP Right Cessation
- 2007-02-13 ES ES07701315T patent/ES2365028T3/es active Active
- 2007-02-13 WO PCT/AT2007/000071 patent/WO2007092978A1/de not_active Ceased
- 2007-02-13 EP EP07701315A patent/EP1984005B1/de active Active
-
2008
- 2008-08-13 US US12/190,759 patent/US7919486B2/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5525598A (en) * | 1991-07-25 | 1996-06-11 | Phillippe Collery | Gallium (III) complexes in pharmaceutical compositions |
| WO2002074304A2 (de) * | 2001-03-19 | 2002-09-26 | Faustus Forschungs Cie. Translational Cancer Research Gmbh | Zusammensetzung, enthaltend einen gallium(iii)-komplex und ein therapeutisch wirksames zytostatikum |
Non-Patent Citations (1)
| Title |
|---|
| P. COLLERY ET AL., ''NEW GALLIUM COMPLEXES FOR A CISPLATIN COMBINATION THERAPY'', METAL IONS IN BIOLOGY AND MEDICINE, 1992, VOL. 2, SEITEN 173-175 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101466387A (zh) | 2009-06-24 |
| JP5210888B2 (ja) | 2013-06-12 |
| PT1984005E (pt) | 2011-07-11 |
| JP2009525987A (ja) | 2009-07-16 |
| ES2365028T3 (es) | 2011-09-20 |
| NZ571119A (en) | 2011-11-25 |
| US20090137620A1 (en) | 2009-05-28 |
| CA2640509A1 (en) | 2007-08-23 |
| WO2007092978A1 (de) | 2007-08-23 |
| CA2640509C (en) | 2014-07-08 |
| EP1984005B1 (de) | 2011-04-06 |
| EP1984005A1 (de) | 2008-10-29 |
| DE502007006880D1 (de) | 2011-05-19 |
| ATE504307T1 (de) | 2011-04-15 |
| AU2007215363A1 (en) | 2007-08-23 |
| AT503317A4 (de) | 2007-09-15 |
| US7919486B2 (en) | 2011-04-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE2318019C2 (de) | Cis-Pt(II)-Koordinationsverbindungen, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltendes pharmazeutisches Mittel | |
| DE69931766T2 (de) | Antitumorale mittel | |
| DE60004348T2 (de) | Kombinierte vorbereitungen, die morpholin anthracyclin und platin derivate | |
| DE10103565B4 (de) | Zusammensetzungen, enthaltend einen Ruthenium(III)-komplex und einen Heterocyclus | |
| EP1984005B1 (de) | Verwendung von gallium (iii) komplexen zur behandlung von melanomen | |
| EP0191096A1 (de) | Tumorhemmend wirkende rutheniumverbindungen. | |
| DE10141528B4 (de) | Platin(II)- und Platin(IV)-Komplexe und ihre Verwendung | |
| AT501819B1 (de) | Verwendung von gallium(iii)-komplexen zur behandlung von tumorerkrankungen der leber | |
| EP0835112B1 (de) | Arzneimittelzubereitungen enthaltend tumorhemmend wirkende ruthenium(iii)-komplexe | |
| WO2002074304A2 (de) | Zusammensetzung, enthaltend einen gallium(iii)-komplex und ein therapeutisch wirksames zytostatikum | |
| AT501262B1 (de) | Verwendung von gallium(iii)-komplexen zur behandlung von tumoren des urothelialtraktes | |
| AT505367A1 (de) | Tumorhemmende ruthenium und osmium- thiosemicarbazonatokomplexe | |
| EP1414829A2 (de) | Tumorhemmende cerverbindungen | |
| WO2002076993A1 (de) | Tumorhemmende siliciumverbindungen | |
| DE10116527C2 (de) | Tumorhemmende Galliumverbindungen, deren Verwendung als Arzneimittel sowie ein Arzneimittel, diese enthaltend | |
| WO2003016318A1 (de) | Tumorhemmende lanthanverbindungen | |
| DE10114106C1 (de) | Tumorhemmende Siliciumverbindungen, Verfahren zu ihrer Herstellung und deren Verwendung als Arzneimittel | |
| WO2004075887A1 (de) | Verwendung von 1-(2-chlorethyl)-1-nitroso-3-(2-hydroxyethyl)-urea zur behandlung von pankreaskarzinomen, weichteilsarkomen, hodentumoren, lymphomen, thymomen, wilms tumoren, nierenkarzinomen, melanomen, lungentumoren, intracerebralen metastasen, tumoren im kopf- und halsbereich, und mamma-karzinomen | |
| DE60003328T2 (de) | Ruthenium (ii) komplexe mit hoher antitumor und antimetastatischer wirkung | |
| AT503592A1 (de) | Tumorhemmende galliumverbindungen | |
| DE10218312C1 (de) | Tumorhemmende Siliziumverbindungen, diese enthaltende Arzneimittel und deren Verwendung | |
| DE19701692A1 (de) | Antineoplastisch wirkende Metallkomplexe und diese enthaltende Arzneimittel | |
| AU2013206221A1 (en) | Use of gallium (III) complexes for the treatment of melanomas | |
| DE3048109A1 (de) | Antineoplastisch wirkende arzneimittel |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ELJ | Ceased due to non-payment of the annual fee |